LY-3143921

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameLY-3143921
Drug Alias NameLY-3143921 hydrateLY-3143921
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCell division cycle 7-related protein kinase inhibitors
TargetsCell division cycle 7-related protein kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyCancer Research UK
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A